Validation of a real-time quantitative polymerase chain reaction method for the quantification of 3 Survivin transcripts and evaluation in breast cancer tissues

Clinical Breast Cancer

Volumn 14, Issue 2, 2014, Pages 122-131

  Pavlidou, Anastasia ^a   Kroupis, Christos ^a   Goutas, Nikolaos ^b   Dalamaga, Maria ^a   Dimas, Kleanthi ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Apoptosis; Dual hybridization probes; Prognostic biomarkers; qPCR; Survivin splice variants

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; SURVIVIN; SURVIVIN 2B; SURVIVIN DELTAEX3; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ARTICLE; BREAST CANCER; CANCER GRADING; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REAL TIME QUANTITATIVE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; VALIDATION STUDY;

APOPTOSIS; DUAL HYBRIDIZATION PROBES; PROGNOSTIC BIOMARKERS; QPCR; SURVIVIN SPLICE VARIANTS;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PROGNOSIS; PROTEIN ISOFORMS; RNA SPLICING; SURVIVAL RATE;

EID: 84896405653     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.10.012     Document Type: Article

References (47)

1. J. Ferlay, H.R. Shin, and F. Bray et al. GLOBOCAN 2008 v2.0, cancer incidence and mortality worldwide: IARC CancerBase no. 10 [internet] 2010 International Agency for Research on Cancer Lyon, France Available at: http://globocan.iarc.fr Accessed: June 5, 2013
2. A.C. Mita, M.M. Mita, and S.T. Nawrocki et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics Clin Cancer Res 14 2008 5000 5005
3. B. Ryan, N. O'Donovan, and B. Browne et al. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer Br J Cancer 92 2005 120 124 (Pubitemid 40188444)
4. D. Xie, Y.X. Zeng, and H.J. Wang et al. Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma Br J Cancer 94 2006 108 114 (Pubitemid 43088549)
5. J.J. Virrey, S. Guan, and W. Li et al. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells Am J Pathol 173 2008 75 85
6. C. Mahotka, M. Wenzel, and E. Springer et al. Survivin-deltaEx3 and survivin-2B: 2 novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties Cancer Res 59 1999 6097 6102 (Pubitemid 30035627)
7. X. Ling, Q. Cheng, and J.D. Black et al. Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin J Biol Chem 282 2007 27204 27214 (Pubitemid 47501974)
8. K. Suga, T. Yamamoto, and Y. Yamada et al. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas Oncol Rep 13 2005 891 897
9. A. Pavlidou, M. Dalamaga, and C. Kroupis et al. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR World J Gastroenterol 17 2011 1614 1621
10. S. Paik, S. Shak, and G. Tang et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2004 2817 2826 (Pubitemid 40051905)
11. K.S. Albain, W.E. Barlow, and S. Shak et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Lancet Oncol 11 2010 55 65
12. C. Genestie, B. Zafrani, and B. Asselain et al. Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems Anticancer Res 18 1998 571 576 (Pubitemid 28174874)
13. E. Zygalaki, A. Stathopoulou, and C. Kroupis et al. Real-time reverse transcription-PCR quantification of vascular endothelial growth factor splice variants Clin Chem 51 2005 1518 1520 (Pubitemid 41060890)
14. C. Kroupis, A. Stathopoulou, and E. Zygalaki et al. Development and applications of a real-time quantitative RT-PCR method (QRT-PCR)for BRCA1 mRNA Clin Biochem 38 2005 50 57 (Pubitemid 39647656)
15. J. Huggett, K. Dheda, and S. Bustin et al. Real-time RT-PCR normalisation; strategies and considerations Genes Immun 6 2005 279 284 (Pubitemid 40903399)
16. S.A. Bustin Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems J Mol Endocrinol 29 2002 23 39 (Pubitemid 34965744)
17. C. Tricarico, P. Pinzani, and S. Bianchi et al. Quantitative real-time reverse transcription polymerase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies Anal Biochem 309 2002 293 300 (Pubitemid 35387321)
18. A. Badran, A. Yoshida, and K. Ishikawa et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin Biochem Biophys Res Commun 314 2004 90290 90297
19. H. Caldas, L.E. Honsey, and R.A. Altura Survivin 2alpha: a novel survivin splice variant expressed in human malignancies Mol. Cancer 4 2005 11
20. G. Mola, E. Vela, and M.T. Fernández-Figueras et al. Exonization of Alu-generated splice variants in the survivin gene of human and non-human primates J Mol Biol 366 2007 1055 1063 (Pubitemid 46188640)
21. H. Caldas, Y. Jiang, and M.P. Holloway et al. Survivin splice variants regulate the balance between proliferation and cell death Oncogene 24 2005 1994 2007 (Pubitemid 40520508)
22. M. Espinosa, G. Ceballos-Cancino, and R. Callaghan et al. Survivin isoform Delta Ex3 regulates tumor spheroid formation Cancer Lett 318 2012 61 67
23. H. Futakuchi, M. Ueda, and K. Kanda et al. Transcriptional expression of survivin and its splice variants in cervical carcinomas Int J Gynecol Cancer 17 2007 1092 1098 (Pubitemid 47414808)
24. X.N. Li, Q. Shu, and J.M. Su et al. Differential expression of survivin splice isoforms in medulloblastomas Neuropathol Appl Neurobiol 33 2007 67 76 (Pubitemid 46090311)
25. S. Mandayam, R. Huang, and A.S. Tarnawski et al. Roles of survivin isoforms in the chemopreventive actions of NSAIDS on colon cancer cells Apoptosis 12 2007 1109 1116 (Pubitemid 46701598)
26. P.N. Span, V.C. Tjan-Heijnen, and J.J. Heuvel et al. Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clin Chem 52 2006 1693 1700 (Pubitemid 44330703)
27. B.M. Ryan, G.E. Konecny, and S. Kahlert et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1 Ann Oncol 17 2006 597 604
28. S.K. Knauer, C. Bier, and P. Schlag et al. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein Cell Cycle 6 2007 1502 1509
29. F. Végran, R. Boidot, and F. Bonnetain et al. Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma Endocr Relat Cancer 18 2011 783 792
30. H. Meng, C. Lu, and H. Mabuchi et al. Prognostic significance and different properties of survivin splicing variants in gastric cancer Cancer Lett 216 2004 147 155 (Pubitemid 39463318)
31. G.S. Cho, T.S. Ahn, and D. Jeong et al. Expression of the survivin-2B splice variant related to the progression of colorectal carcinoma J Korean Surg Soc 80 2011 404 411
32. M. Zhang, J. Yang, and F. Li Transcriptional and posttranscriptional controls of survivin in cancer cells: essential interfaces for developing novel approaches for cancer treatment J Exp Clin Cancer Res 25 2006 391
33. T. Nolan, R.E. Hands, and W. Ogunkolade et al. SPUD: a quantitative PCR assay for the detection of inhibitors in nucleic acid preparations Anal Biochem 351 2006 308 310
34. T. Nolan, R.E. Hands, and S.A. Bustin Quantification of mRNA using real-time RT-PCR Nat Protoc 1 2006 1559 1582
35. M.T. Tomicic, and B. Kaina Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors Biochim Biophys Acta 1835 2013 11 27
36. R. Díaz, J.M. González-Sancho, and B. Soldevilla et al. Differential regulation of TP73 isoforms by 1α,25-dihydroxyvitamin D3 and survivin in human colon and breast carcinomas Genes Chromosomes Cancer 49 2010 1135 1142
37. P. Gazzaniga, A. Gradilone, and A. Petracca et al. Molecular markers in circulating tumour cells from metastatic colorectal cancer patients J Cell Mol Med 14 2010 2073 2077
38. B.S. Wittner, D.C. Sgroi, and P.D. Ryan et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort Clin Cancer Res 14 2008 2988 2993
39. L.J. Solin, R. Gray, and F.L. Baehner et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast J Natl Cancer Inst 105 2013 701 710
40. N. Poumpouridou, and C. Kroupis Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges Clin Chem Lab Med 50 2012 423 434
41. M. Pennati, M. Folini, and N. Zaffaroni Targeting survivin in cancer therapy Expert Opin Ther Targets 12 2008 463 476 (Pubitemid 351551639)
42. Q. Fei, H. Zhang, and L. Fu et al. Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes Acta Biochim Biophys Sin (Shanghai) 40 2008 466 477 (Pubitemid 351847347)
43. D. Kunze, K. Kraemer, and K. Erdmann et al. Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells Int J Oncol 41 2012 1271 1277
44. T. Tsuruma, Y. Iwayama, and T. Ohmura et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer J Transl Med 6 2008 24
45. Y.Q. Wang, H.H. Zhang, and C.L. Liu et al. Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model Int Immunopharmacol 17 2013 9 17
46. E.R. Manuel, C.A. Blache, and J.D. Ellenhorn et al. Survivin the battle against immunosuppression Oncoimmunology 1 2012 240 241
47. K. Miura, W. Fujibuchi, and M. Unno Splice isoforms as therapeutic targets for colorectal cancer Carcinogenesis 33 2012 2311 2319